Emisphere Technologies Inc. on Thursday announced acollaboration with SciClone Pharmaceuticals Inc. to work on thedevelopment of oral dosage formulations for a number ofexisting and future SciClone products. Emisphere could receivemilestone payments as feasibility and development steps areachieved.

Emisphere also said it has filed with the Securites and ExchangeCommision a public offering of 1.8 million shares of commonstock (NASDAQ:EMIS), of which 1.5 million are being sold bythe company.

Emisphere of Hawthrone, N.Y., is working on developing andcommercializing its proprietary oral delivery system. SciClone(NASDAQ:SCLN) of San Mateo, Calif., is primarily engaged in theacquisition, development and marketing of pharmaceuticals ona worldwide basis.

SciClone and its licenser, Alpha 1 Biomedicals Inc.(NASDAQ:ALBM) also announced Thursday that they receivedFDA approval to export Thymosin alpha 1 to Mexico for aclinical trial for chronic hepatitis B.

-- Nancy Garcia Associate Editor

(c) 1997 American Health Consultants. All rights reserved.

No Comments